Lifeward Ltd Dossier
Qualitative Analysis
Business overview
Lifeward Ltd. (formerly ReWalk Robotics Ltd.) is a pioneer and global leader in the design, development, and commercialization of life-changing solutions that span the continuum of care in physical rehabilitation and recovery. The company's commercialized neurorehabilitation portfolio features the ReWalk Personal Exoskeleton (the first exoskeleton to receive FDA clearance for personal use), the AlterG Anti-Gravity Systems, the MyoCycle Functional Electrical Stimulation (FES) Systems, and the ReStore Exo-Suit. In early 2026, Lifeward completed a transformative strategic transaction with Oramed Pharmaceuticals, acquiring its clinical-stage Protein Oral Delivery (POD™) technology platform (including lead asset ORMD-0801 oral insulin) and the Oratech asset acquisition, effectively repositioning itself as a diversified biomedical innovation company blending established MedTech hardware with high-upside biotech pipelines.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting the company from a pure-play neurorehabilitation medtech firm into a diversified biomedical innovation company by integrating Oramed's Protein Oral Delivery (POD) technology platform.
Expected impact: Combines near-term medtech commercial revenue with high-upside, long-term biotech pipeline opportunities, specifically targeting the large injectable drug delivery market.
Acquiring and developing Skelable's robotic upper-body orthotic technology with integrated AI capabilities to expand the product portfolio beyond lower-limb mobility solutions.
Expected impact: Addresses a major unmet clinical need for 245,000 newly diagnosed U.S. stroke survivors annually with upper-limb impairments, leveraging existing prescriber and payer channels.
Expanding global access to the ReWalk Personal Exoskeleton by combining direct sales in the United States and Germany with strategic third-party distribution partnerships in select international markets.
Expected impact: Accelerates international market penetration in Mexico, Thailand, and the UAE while managing operating expenses and driving sustainable sales volume growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Oratech brings Oramed's proprietary Protein Oral Delivery (POD) technology platform and lead clinical-stage oral insulin candidate ORMD-0801, transforming Lifeward into a diversified biomedical innovator.
Financial impact: Bolstered the balance sheet by adding $6.5 million in cash acquired at close, alongside a $10 million convertible note financing, while incurring a one-time, non-cash $4.9 million in-process R&D charge in Q1 2026.
Acquisition of intellectual property, functional prototypes, and know-how for a robotic upper-body orthotic device with AI capabilities to expand Lifeward's neurorehabilitation portfolio.
Financial impact: Structured predominantly as equity to limit immediate cash outlay, with up to $480,000 payable in Lifeward ordinary shares in installments tied to milestones and $20,000 in cash.
Strategic Partnerships
Provides Lifeward with a robust cash runway toward profitability for its MedTech lines while Oramed funds and manages the clinical development of the acquired POD platform, preserving Lifeward's operational focus.
Terms: Oramed acquires up to a 49.99% equity stake in Lifeward. Lifeward receives access to up to $47 million in capital through equity, convertible notes, and warrants. Oramed will receive a 4% royalty on net sales of the ReWalk franchise for up to 10 years.
Expands patient access to the ReWalk Personal Exoskeleton in key international markets (Mexico, Thailand, and the UAE) by integrating the device into Verita Neuro's intensive in-patient neurorehabilitation programs.
Terms: Verita Neuro acts as the exclusive distributor in the specified regions, utilizing its database of over 25,000 spinal cord injury patients to drive clinical adoption.